Login Register Cart 0
Systematic Review Article

The Effectiveness of Nanoparticles on Gene Therapy for Glioblastoma Cells Apoptosis: A Systematic Review

Author(s): Firoozeh Alavian and Sorayya Ghasemi*

Volume 21, Issue 3, 2021

Published on: 24 February, 2021

Page: [230 - 245] Pages: 16

DOI: 10.2174/1566523221666210224110454

Price: $65

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and fatal type of glioma. Nanoparticles (NPs) are used in new approaches for the delivery of gene therapy in the treatment of GBM.

Introduction: The purpose of this article was to review the efficacy of NPs as the targeted carriers in the gene therapy aimed at apoptosis in GBM.

Methods: The appropriate keywords such as nanoparticle, glioblastoma, gene therapy, apoptosis, and related words were used to search from PubMed, ISI Web of Science, and Scopus for relevant publications up to September 4, 2020, with no language restrictions. The present systematic review was performed based on PRISMA protocol and reviewed the articles evaluating the effects of nanoparticles, carriers of various gene therapies essentials, on GBM cells apoptosis in vitro and in vivo. The selected articles were considered using specific scores on the quality of the articles. Data extraction and quality evaluation were performed by two reviewers.

Results: Of 101 articles retrieved, forty-two met the inclusion criteria and were, therefore, subjected to the final deduction. The most widely used NP in GBM gene therapy studies is polyamidoamine (PAMAM). The most common gene therapy approach for apoptosis in GBM is using siRNAs.

Conclusion: In conclusion, these studies validated that NPs could be a practical choice to enhance the efficiency and specific delivery in gene therapies for GBM cell apoptosis. However, the choice of NP type and gene therapy mechanism affect the GBM cell apoptotic efficiency.

Keywords: Nanoparticle, gene therapy, glioblastoma, apoptosis, PRISMA, polyamidoamine.

« Previous Next »
Graphical Abstract

[1]
Caffery B, Lee JS, Alexander-Bryant AA. Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies. Nanomaterials (Basel) 2019; 9(1): 105.
[http://dx.doi.org/10.3390/nano9010105] [PMID: 30654536]
[2]
Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005; 7(1): 7-16.
[http://dx.doi.org/10.1593/neo.04535] [PMID: 15720813]
[3]
Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005; 26(2): 263-70.
[http://dx.doi.org/10.1093/carcin/bgh283] [PMID: 15375012]
[4]
Nikalje AP. Nanotechnology and its applications in medicine. Med chem 2015; 5(2): 081-9.
[http://dx.doi.org/10.4172/2161-0444.1000247]
[5]
Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J 2018; 26(1): 64-70.
[http://dx.doi.org/10.1016/j.jsps.2017.10.012] [PMID: 29379334]
[6]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6(7): e1000100.
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[7]
Viseu T, Lopes CM, Fernandes E, Oliveira MECDR, Lúcio M. A Systematic Review and Critical Analysis of the Role of Graphene-Based Nanomaterialsin Cancer Theranostics. Pharmaceutics 2018; 10(4): 282.
[http://dx.doi.org/10.3390/pharmaceutics10040282] [PMID: 30558378]
[8]
Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging therapeutic potential of nanoparticles in pancreatic cancer: a systematic review of clinical trials. Biomedicines 2016; 4(3): 20.
[http://dx.doi.org/10.3390/biomedicines4030020] [PMID: 28536387]
[9]
Zhou P, Cao Y, Liu X, et al. Delivery siRNA with a novel gene vector for glioma therapy by targeting Gli1. Int J Nanomedicine 2018; 13: 4781-93.
[http://dx.doi.org/10.2147/IJN.S164364] [PMID: 30214189]
[10]
Wang X, Hua Y, Xu G, Deng S, Yang D, Gao X. Targeting EZH2 for glioma therapy with a novel nanoparticle-siRNA complex. Int J Nanomedicine 2019; 14: 2637-53.
[http://dx.doi.org/10.2147/IJN.S189871] [PMID: 31043779]
[11]
Shatsberg Z, Zhang X, Ofek P, et al. Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. J Control Release 2016; 239: 159-68.
[http://dx.doi.org/10.1016/j.jconrel.2016.08.029] [PMID: 27569663]
[12]
Gao S, Li J, Jiang C, Hong B, Hao B. Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. Drug Des Devel Ther 2015; 10: 1-11.
[http://dx.doi.org/10.2147/DDDT.S95843] [PMID: 26719669]
[13]
Mangraviti A, Tzeng SY, Kozielski KL, et al. Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano 2015; 9(2): 1236-49.
[http://dx.doi.org/10.1021/nn504905q] [PMID: 25643235]
[14]
Huang S, Li J, Han L, et al. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 2011; 32(28): 6832-8.
[http://dx.doi.org/10.1016/j.biomaterials.2011.05.064] [PMID: 21700333]
[15]
Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev 2017; 46(14): 4218-44.
[http://dx.doi.org/10.1039/C6CS00636A] [PMID: 28585944]
[16]
ud Din, F.; Aman, W.; Ullah, I.; Qureshi, O.S.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine 2017; 12: 7291.
[http://dx.doi.org/10.2147/IJN.S146315]
[17]
Mali S. Delivery systems for gene therapy. Indian J Hum Genet 2013; 19(1): 3-8.
[http://dx.doi.org/10.4103/0971-6866.112870] [PMID: 23901186]
[18]
Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15(2): 65-77.
[http://dx.doi.org/10.1002/jgm.2698] [PMID: 23355455]
[19]
Zhou L-Y, Qin Z, Zhu Y-H, He Z-Y, Xu T. Current RNA-based therapeutics in clinical trials. Curr Gene Ther 2019; 19(3): 172-96.
[http://dx.doi.org/10.2174/1566523219666190719100526] [PMID: 31566126]
[20]
Pishavar E, Attaranzadeh A, Alibolandi M, Ramezani M, Hashemi M. Modified PAMAM vehicles for effective TRAIL gene delivery to colon adenocarcinoma: in vitro and in vivo evaluation. Artificial cells, nanomedicine, and biotechnology 2018; 46(sup3): S503-13.
[http://dx.doi.org/10.1080/21691401.2018.1500372]
[21]
Pourianazar NT, Mutlu P, Gunduz U. Bioapplications of poly (amidoamine)(PAMAM) dendrimers in nanomedicine. J Nanopart Res 2014; 16(4): 2342.
[http://dx.doi.org/10.1007/s11051-014-2342-1]
[22]
Ghasemi S, Alavian K, Alavian F. Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review. Curr Gene Ther 2020; 20(5): 373-82.
[http://dx.doi.org/10.2174/1566523220666201012150130] [PMID: 33045966]
[23]
Dundar TT, Hatiboglu MA, Ergul Z, et al. Glioblastoma Stem Cells and Comparison of Isolation Methods. J Clin Med Res 2019; 11(6): 415-21.
[http://dx.doi.org/10.14740/jocmr3781] [PMID: 31143308]
[24]
Ma C-C, Wang Z-L, Xu T, He Z-Y, Wei Y-Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv 2020; 40: 107502.
[http://dx.doi.org/10.1016/j.biotechadv.2019.107502] [PMID: 31887345]
[25]
Dong Z, Qin Q, Hu Z, et al. Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms. Virol Sin 2019; 34(4): 444-53.
[http://dx.doi.org/10.1007/s12250-019-00121-4] [PMID: 31218589]
[26]
Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. Int J Nanomedicine 2017; 12: 8483-93.
[http://dx.doi.org/10.2147/IJN.S148359] [PMID: 29238188]
[27]
Sapre AA, Yong G, Yeh YS, et al. Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity. J Control Release 2019; 297: 48-59.
[http://dx.doi.org/10.1016/j.jconrel.2019.01.034] [PMID: 30690106]
[28]
Kozielski KL, Ruiz-Valls A, Tzeng SY, et al. Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. Biomaterials 2019; 209: 79-87.
[http://dx.doi.org/10.1016/j.biomaterials.2019.04.020] [PMID: 31026613]
[29]
Zhu L, Oh JM, Gangadaran P, et al. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells. Front Immunol 2018; 9: 824.
[http://dx.doi.org/10.3389/fimmu.2018.00824] [PMID: 29740437]
[30]
Zhu L, Gangadaran P, Kalimuthu S, et al. Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells. Artif Cells Nanomed Biotechnol 2018; 46(sup3): S166-79.
[http://dx.doi.org/10.1080/21691401.2018.1489824] [PMID: 30092165]
[31]
Yang Y, Du T, Zhang J, et al. A 3D-Engineered Conformal Implant Releases DNA Nanocomplexs for Eradicating the Postsurgery Residual Glioblastoma. Adv Sci (Weinh) 2017; 4(8): 1600491.
[http://dx.doi.org/10.1002/advs.201600491] [PMID: 28852611]
[32]
Wang S, Reinhard S, Li C, et al. Antitumoral cascade-targeting ligand for IL-6 receptor-mediated gene delivery to glioma. Mol Ther 2017; 25(7): 1556-66.
[http://dx.doi.org/10.1016/j.ymthe.2017.04.023] [PMID: 28502470]
[33]
Lee TJ, Yoo JY, Shu D, et al. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. Mol Ther 2017; 25(7): 1544-55.
[http://dx.doi.org/10.1016/j.ymthe.2016.11.016] [PMID: 28109960]
[34]
Kievit FM, Wang K, Ozawa T, et al. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine (Lond) 2017; 13(7): 2131-9.
[http://dx.doi.org/10.1016/j.nano.2017.06.004] [PMID: 28614736]
[35]
Huang JL, Jiang G, Song QX, et al. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat Commun 2017; 8: 15144.
[http://dx.doi.org/10.1038/ncomms15144] [PMID: 28489075]
[36]
Eslaminejad T, Nematollahi-Mahani SN, Ansari M. Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles. Curr Gene Ther 2017; 17(1): 59-69.
[http://dx.doi.org/10.2174/1566523217666170605115829] [PMID: 28578643]
[37]
Bae Y, Rhim HS, Lee S, Ko KS, Han J, Choi JS. Apoptin Gene Delivery by the Functionalized Polyamidoamine Dendrimer Derivatives Induces Cell Death of U87-MG Glioblastoma Cells. J Pharm Sci 2017; 106(6): 1618-33.
[http://dx.doi.org/10.1016/j.xphs.2017.01.034] [PMID: 28188727]
[38]
Tzeng SY, Wilson DR, Hansen SK, Quiñones-Hinojosa A, Green JJ. Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. Bioeng Transl Med 2016; 1(2): 149-59.
[http://dx.doi.org/10.1002/btm2.10019] [PMID: 28349127]
[39]
Gao S, Tian H, Xing Z, et al. A non-viral suicide gene delivery system traversing the blood brain barrier for non-invasive glioma targeting treatment. J Control Release 2016; 243: 357-69.
[http://dx.doi.org/10.1016/j.jconrel.2016.10.027] [PMID: 27794494]
[40]
Bae Y, Green ES, Kim GY, et al. Dipeptide-functionalized polyamidoamine dendrimer-mediated apoptin gene delivery facilitates apoptosis of human primary glioma cells. Int J Pharm 2016; 515(1-2): 186-200.
[http://dx.doi.org/10.1016/j.ijpharm.2016.09.083] [PMID: 27732896]
[41]
Yao H, Wang K, Wang Y, et al. Enhanced blood-brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. Biomaterials 2015; 37: 345-52.
[http://dx.doi.org/10.1016/j.biomaterials.2014.10.034] [PMID: 25453963]
[42]
Wang X, Zhu L, Hou X, Wang L, Yin S. Polyethylenimine mediated magnetic nanoparticles for combined intracellular imaging, siRNA delivery and anti-tumor therapy. RSC Advances 2015; 5(123): 101569-81.
[http://dx.doi.org/10.1039/C5RA18464A]
[43]
Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG, Zhang M. Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma. Adv Healthc Mater 2015; 4(17): 2719-26.
[http://dx.doi.org/10.1002/adhm.201500563] [PMID: 26498165]
[44]
Leten C, Trekker J, Struys T, et al. Assessment of bystander killing-mediated therapy of malignant brain tumors using a multimodal imaging approach. NanoStem Cell Res Ther 2015; 6(1): 163.
[http://dx.doi.org/10.1186/s13287-015-0157-3] [PMID: 26345383]
[45]
Costa PM, Cardoso AL, Custódia C, Cunha P, Pereira de Almeida L, Pedroso de Lima MC. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. J Control Release 2015; 207: 31-9.
[http://dx.doi.org/10.1016/j.jconrel.2015.04.002] [PMID: 25861727]
[46]
Cohen ZR, Ramishetti S, Peshes-Yaloz N, et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 2015; 9(2): 1581-91.
[http://dx.doi.org/10.1021/nn506248s] [PMID: 25558928]
[47]
Zamora G, Wang F, Sun CH, et al. Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier. J Biomed Opt 2014; 19(10): 105009.
[http://dx.doi.org/10.1117/1.JBO.19.10.105009] [PMID: 25341069]
[48]
Yata T, Lee KY, Dharakul T, et al. Hybrid nanomaterial complexes for advanced phage-guided gene delivery. Mol Ther Nucleic Acids 2014; 3: e185.
[http://dx.doi.org/10.1038/mtna.2014.37] [PMID: 25118171]
[49]
Wan Y, Apostolou S, Dronov R, Kuss B, Voelcker NH. Cancer-targeting siRNA delivery from porous silicon nanoparticles. Nanomedicine 2014; 9(15): 2309-21.
[http://dx.doi.org/10.2217/nnm.14.12]
[50]
Kim SS, Rait A, Kim E, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 2014; 8(6): 5494-514.
[http://dx.doi.org/10.1021/nn5014484] [PMID: 24811110]
[51]
Ediriwickrema A, Zhou J, Deng Y, Saltzman WM. Multi-layered nanoparticles for combination gene and drug delivery to tumors. Biomaterials 2014; 35(34): 9343-54.
[http://dx.doi.org/10.1016/j.biomaterials.2014.07.043] [PMID: 25112935]
[52]
Yin T, Wang P, Li J, et al. Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials 2013; 34(18): 4532-43.
[http://dx.doi.org/10.1016/j.biomaterials.2013.02.067] [PMID: 23522375]
[53]
Li J, Guo Y, Kuang Y, An S, Ma H, Jiang C. Choline transporter-targeting and co-delivery system for glioma therapy. Biomaterials 2013; 34(36): 9142-8.
[http://dx.doi.org/10.1016/j.biomaterials.2013.08.030] [PMID: 23993342]
[54]
Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 2013; 5(209): ra152.
[http://dx.doi.org/10.1126/scitranslmed.3006839] [PMID: 24174328]
[55]
Gaca S, Reichert S, Multhoff G, et al. Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. J Control Release 2013; 172(1): 201-6.
[http://dx.doi.org/10.1016/j.jconrel.2013.08.020] [PMID: 24008150]
[56]
Bai CZ, Choi S, Nam K, An S, Park JS. Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. Int J Pharm 2013; 445(1-2): 79-87.
[http://dx.doi.org/10.1016/j.ijpharm.2013.01.057] [PMID: 23384727]
[57]
An S, Nam K, Choi S, Bai CZ, Lee Y, Park JS. Nonviral gene therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeutic. Int J Nanomedicine 2013; 8: 821-34.
[http://dx.doi.org/10.2147/IJN.S39072] [PMID: 23589689]
[58]
Qian X, Ren Y, Shi Z, et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm 2012; 9(9): 2636-45.
[http://dx.doi.org/10.1021/mp3002039] [PMID: 22853427]
[59]
Huang R, Ke W, Han L, Li J, Liu S, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials 2011; 32(9): 2399-406.
[http://dx.doi.org/10.1016/j.biomaterials.2010.11.079] [PMID: 21185076]
[60]
Kang C, Yuan X, Li F, et al. Evaluation of folate-PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo. J Biomed Mater Res A 2010; 93(2): 585-94.
[http://dx.doi.org/10.1002/jbm.a.32525] [PMID: 19591231]
[61]
Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006; 66(24): 11878-87.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-2354] [PMID: 17178885]
[62]
Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 2001; 8(9): 649-54.
[http://dx.doi.org/10.1038/sj.cgt.7700357] [PMID: 11593333]
[63]
Van Woensel M, Mathivet T, Wauthoz N, et al. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Sci Rep 2017; 7(1): 1217.
[http://dx.doi.org/10.1038/s41598-017-01279-1] [PMID: 28450700]
[64]
Liu XZ, Su ZG, Jiang ZM, et al. Inhibitory effect of folic acid/polyamide-amine as a miR-7 vector on the growth of glioma in mice. Zhonghua Zhong Liu Za Zhi 2012; 34(5): 325-30.
[http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2012.05.002] [PMID: 22883450]

Rights & Permissions Print Cite
Article Metrics
37
1
© 2024 Bentham Science Publishers | Privacy Policy